Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Increase in Resources Estimates in Shanagarry

10 Apr 2013 07:00

RNS Number : 9661B
Fastnet Oil & Gas PLC
10 April 2013
 



10 April 2013

Fastnet Oil & Gas Plc announces

Significant Increase in Independent Resources Estimates in its North Celtic Sea

Licensing Option 12/5 ("Shanagarry")

 

 Highlights of Independent Resources Estimates:

 

§ 123 sq. km. structure updip from oil and gas bearing intervals in the 49/19-1 Shanagarry structure

 

§ Multiple reservoir targets consistent with analogous tested and producing intervals in Barryroe and Kinsale oil and gas fields

 

§ Aggregated unrisked gross P50 Best Case Prospective resources of 1.298 billion barrels of oil in-place and 1.342 TCF of gas in-place

 

§ Geological Chances of Success vary from 12 to 14% for oil reservoirs and 5 to 10% for gas reservoirs

 

Fastnet Oil & Gas plc ("Fastnet" or the "Company") (AIM: FAST, ESM: FOI) the E&P company focused on near term exploration acreage in Morocco and the Celtic Sea, is pleased to announce that an independent assessment of the Company's prospective resources on licensing option 12/5 ("Shanagarry" or the "Licensing Option") has been completed by SLR Consulting. Fastnet farmed-into thelicence on 14 November 2012 and now operates and holds an 82.35% working interest in Shanagarry following ministerial consent received on 8th April 2013. The independent assessment was carried out in accordance with generally accepted international standards. The following table has been prepared by Fastnet for the convenience of readers to summarise prospective hydrocarbon resources in the 49/19-1 Shanagarry structure ("49/19-1") and the associated geological chance of success ("GCoS").

 

UNRISKED GROSS PROSPECTIVE RESOURCES (49/19-1 SHANAGARRY STRUCTURE) AS AT 9 APRIL 2013

 

P50 BEST CASE

STOIP (MM BO)

GIIP (BCF)

GCoS

UPPER WEALDEN

135.9

10%

LOWER WEALDEN

796.6

14%

PURBECK

501.6

12%

KIMMERIDGIAN/PORTLANDIAN

885.7

5%

MIDDLE/UPPER JURASSIC (GAS)

321.1

5%

TOTAL*

1,298.2

1,342.7

*See Note 4 in the "Notes to Editors" section below.

 

49/19-1 covers an area of 123 sq. km., making it one of the more significant hydrocarbon-bearing structures in the North Celtic Sea. Four hydrocarbon-bearing intervals were encountered in 49/19-1, whilst the Upper Wealden may potentially be hydrocarbon-bearing updip from the well based on offset gas discoveries at Ardmore and Old Head.

 

Purbeck and Lower Wealden reservoirs, oil-bearing in 49/19-1, form the lowest risked reservoir objectives. STOIP estimates are higher than the published P50 estimates for the Middle and Basal Wealden reservoir intervals for Barryroe (April 2013).

 

The Kimmeridgian/Portlandian overpressured "tight gas" and Middle/Upper Jurassic gas-bearing intervals have also been evaluated. Subject to a scoping well design to address the issue of collecting the data required to model the potential for sustainable commercial flow rates, the "tight gas" potential prospective resources could be a viable add-on to a development of the conventional oil and gas prospective resources in the 49/19-1 Shanagarry structure, as a result of economies of scale should the area become a "hub" for appraisal and development. In such a case a number of currently stranded gas assets could also be developed as satellite tie-backs to the hub.

 

The Independent Technical Evaluation Report on the Shanagarry Licensing Option is available to download on the Fastnet website at www.fastnetoilandgas.com .

 

Commenting, Paul Griffiths, MD of Fastnet, said:

 

"SLR Consulting's independent assessment confirms the significant resource potential of Shanagarry. 49/19-1 was drilled by Marathon in 1984 at a time of low oil and gas prices and prior to the discovery and appraisal of Barryroe (Basal Cretaceous oil) and the Dragon Field in Cardigan Bay (Basal Upper Jurassic gas and condensate).It covers an area of 123 sq. km. and is therefore comparable in size to the Kinsale gas field and Barryroe oil field structures. Geological similarities with both Deep Kinsale and Barryroe have now been independently confirmed by SLR Consulting. The addition of running room represented by our Deep Kinsale and 49/19-1 will be an additional positive factor in a potential farm-out or similar transaction. Indeed the prospective resources have now reached a critical threshold for a new entrant wishing to develop an appraisal and development hub in the central Celtic Sea adjacent to the Kinsale gas-gathering infrastructure.

 

"3D seismic over Deep Kinsale may mature prospects for drilling as early as 2014 as part of a multi-well drilling programme with other Celtic Sea operators. We believe the Celtic Sea is set to be transformed over the next 12 months as it once again becomes Ireland's foremost oil and gas basin. Fastnet's 3D seismic programmes and farm-out activity places the Company in a unique position in the Celtic Sea to provide running room for international oil companies seeking to add offshore Ireland to their "core area" portfolios."

 

For further information please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

+353 (1) 644 0007

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

 

Mirabaud Securities LLP

(Joint Broker)

Peter Krens, Edward Haig-Thomas

 

+44 (20) 7321 2508

 

Davy

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

 

+353 (1) 679 6363

 

FTI Consulting

Edward Westropp, Natalia Erikssen, Jess Allum

 

+44 (0) 207 831 3113

 

Notes to editors

Fastnet Oil & Gas plc is an independent oil and gas exploration company that focuses on identifying early stage exploration and appraisal opportunities in Offshore Ireland and Africa. It is quoted on the AIM market of the London Stock Exchange and the Enterprise Securities Market ("ESM") of the Irish Stock Exchange. Fastnet's aim is to assemble a portfolio of high impact conventional oil and gas assets that will deliver sustainable growth and value for the Company. Its immediate focus is on implementing its Offshore Ireland and Africa strategies where it has been awarded four offshore licensing options in the Celtic Sea (Molly Malone Basin, Shanagarry, 49/13 and Mizzen Basin) and acquired a material interest in the highly prospective Foum Assaka permit Offshore Morocco. In addition, Fastnet will continue to pursue new conventional oil and gas opportunities in Africa where the Directors and Advisory Board also have extensive knowledge, contacts and experience of creating value.

 

 

 Notes:

 

1. Prospects are features that are sufficiently well defined, on the basis of geological and geophysical data, to the point where they are considered viable drilling targets.

2. "Gross Unrisked Prospective Resources" are 100% of the volumes estimated to be in-place in a prospective structure.

3. The GCoS reported here represents an indicative estimate of the probability that drilling this Prospect would result in a discovery, which would warrant the re-classification of that volume as a "Contingent Resource". The GCoS value for Contingent Resource is, by definition, unity. These GCoS values have not been arithmetically applied to the designated volumes within this assessment. Thus the volumes are "Unrisked".

4. It is inappropriate to aggregate Prospective Resources without due consideration of the different levels of risk associated with each Prospect and the potential dependencies between them.

5. The above table represents the expected outcomes for an oil and gas discovery based on the nearest analogues being the undeveloped Barryroe oil field and the undeveloped Helvick oil field, 50/6-1 oil discovery and Dragon gas field.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKCDQCBKDBQK
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.